Keyphrases
Adult Patients
100%
Immunosuppression
100%
De Novo Acute Myeloid Leukemia
100%
Normal Karyotype
100%
First Remission
100%
Acute Myeloid Leukemia
62%
Acute Myeloid Leukemia Cells
50%
Leukemia Patients
50%
Cytogenetically Normal Acute Myeloid Leukemia
25%
European LeukemiaNet
25%
Remission
12%
RNA Sequencing (RNA-seq)
12%
T Cell Activation
12%
Chemotherapy Response
12%
Immune Suppression
12%
T Cells
12%
Exome Sequencing
12%
Chemotherapy
12%
T Cell Receptor
12%
Bone Marrow
12%
MHC Class II
12%
Prognostic Factors
12%
Conventional Chemotherapy
12%
Genetic Risk
12%
Combined Analysis
12%
Sequencing Studies
12%
Single-cell RNA Sequencing (scRNA-seq)
12%
Differentially Expressed
12%
Unfavorable Outcome
12%
Favorable Risk
12%
Standard-of-care Chemotherapies
12%
CD4+ T Cell Activation
12%
CD4+ Th1 Cells
12%
Risk Profiling
12%
Medicine and Dentistry
Immunosuppressive Treatment
100%
Acute Myeloid Leukemia
100%
De Novo Acute Myeloid Leukemia
100%
Karyotype
100%
Leukemia Cell
36%
RNA Sequence
18%
T Cell Activation
18%
T-Helper Cell
9%
Receptor
9%
T Cell
9%
Immunosuppressive Drug
9%
Major Histocompatibility Complex
9%
T Lymphocyte Receptor
9%
High Risk Population
9%
Genetic Risk
9%
Exome Sequencing
9%
Th1 Cell
9%
Immunology and Microbiology
Immunosuppression
100%
Myeloid
100%
Karyotype
100%
Leukemia Cell
33%
T Cell Activation
16%
RNA Sequence
16%
T Cell
8%
T-Helper Cell
8%
T Cell Receptor
8%
CD4
8%
Major Histocompatibility Complex
8%
Immunosuppressive Drug
8%
Immunity
8%
Whole Exome Sequencing
8%
High Risk Population
8%
Th1 Cell
8%
Genetic Risk
8%
LAG3
8%